Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse

Joshua D. Lambert, Ross O. Meyers, Barbara N. Timmermann, Robert T. Dorr

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 μg/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 μg/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min·kg.

Original languageEnglish (US)
Pages (from-to)85-90
Number of pages6
JournalJournal of Chromatography B: Biomedical Sciences and Applications
Volume754
Issue number1
DOIs
StatePublished - Apr 15 2001

Keywords

  • Nordihydroguaiaretic acid

ASJC Scopus subject areas

  • Chemistry(all)

Fingerprint

Dive into the research topics of 'Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse'. Together they form a unique fingerprint.

Cite this